Iovance Biotherapeutics Inc

30 Sept 2026, 20:07 UTC

Iovance Biotherapeutics shares are advancing as Wells Fargo raises its price target to $18 and TD Cowen increases its target to $16, citing strong growth prospects.

29 Sept 2026, 20:02 UTC

Iovance Biotherapeutics raised its 2026 revenue guidance to $410M-$420M, driven by strong product demand, as shares advance sharply to a new 52-week high.

24 Sept 2026, 20:02 UTC

Iovance Biotherapeutics shares are sharply higher as Goldman Sachs reinstates a Buy rating with a $15.00 price target, projecting $1.2 billion in sales by 2037.

23 Sept 2026, 20:07 UTC

Iovance Biotherapeutics Inc shares fell sharply amid significant volatility on Wednesday, continuing a decline that began since Tuesday's close.

22 Sept 2026, 23:25 UTC

Iovance Biotherapeutics Inc is trading modestly higher in after-market hours, continuing a broader trend of significant gains over the past month.

21 Sept 2026, 20:06 UTC

Iovance Biotherapeutics Inc shares fell sharply, pulling back from earlier session highs amid broader market trends that have seen declines today.

18 Sept 2026, 23:41 UTC

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

17 Sept 2026, 20:07 UTC

Barclays raised its price target on Iovance Biotherapeutics to $15, maintaining an Overweight rating amid positive survey results for Lifileucel ahead of the IOV-LUN-202 study update.

16 Sept 2026, 19:03 UTC

Iovance Biotherapeutics reported record second-quarter revenue of nearly $100 million and is preparing for multiple data updates, driving shares higher since Tuesday.

15 Sept 2026, 23:01 UTC

Iovance Biotherapeutics is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain the movement.

14 Sept 2026, 20:08 UTC

Iovance Biotherapeutics shares are rising amid discussions of a potential valuation at $16, reflecting levels seen in early 2021. The stock is above its 20-day moving average.

11 Sept 2026, 19:16 UTC

Iovance Biotherapeutics is gaining amid social media discussions about an upcoming conference, with expectations for quarterly revenue exceeding $100 million.

10 Sept 2026, 23:06 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours. The stock has seen three consecutive lower daily finishes despite recent strength over the past month.

9 Sept 2026, 20:07 UTC

Iovance Biotherapeutics Inc shares are lower amid broader market declines, with no specific news identified to explain today's volatility.

4 Sept 2026, 19:46 UTC

Iovance Biotherapeutics shares are higher as the company announces participation in two upcoming healthcare conferences to discuss advancements in TIL therapies.

3 Sept 2026, 23:51 UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

2 Sept 2026, 19:16 UTC

Iovance Biotherapeutics is up today, continuing a trend of three consecutive higher daily closes despite rising global bond yields and no specific news.

1 Sept 2026, 23:06 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours, reflecting a slight decline since Tuesday's close amid rising oil prices and inflation concerns.

31 Aug 2026, 19:36 UTC

Iovance Biotherapeutics shares are lower amid increased interest rate hike expectations and uncertainties regarding its product execution and approvals.

28 Aug 2026, 23:11 UTC

Iovance Biotherapeutics Inc is trading higher in after-market hours, remaining near the upper end of its one-month range and above its 20-day moving average.

27 Aug 2026, 23:01 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid a broader market decline influenced by recent economic data and Fed policy expectations.

26 Aug 2026, 23:46 UTC

Iovance Biotherapeutics is trading higher in after-market hours, showing unusual activity and remaining above its 20-day moving average. No specific news was identified.

25 Aug 2026, 19:16 UTC

TD Cowen maintained a Buy rating on Iovance Biotherapeutics and raised its price target to $10, contributing to the stock's gains since Monday.

24 Aug 2026, 23:26 UTC

Iovance Biotherapeutics shares are higher in after-market trading, continuing an upward trajectory since Monday's close, despite recent declines over three sessions.

21 Aug 2026, 20:02 UTC

Iovance Biotherapeutics is lower in Friday's session, with no specific news identified. The broader market also remains down significantly since Thursday's close.

20 Aug 2026, 23:06 UTC

Iovance Biotherapeutics reached a 52-week high after UBS raised its target price to $7, noting strong second-quarter sales of $91 million.

19 Aug 2026, 23:16 UTC

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

18 Aug 2026, 23:06 UTC

Iovance Biotherapeutics shares were roughly flat in after-market hours. The broader market faced pressure from rising bond yields and increased oil prices.

17 Aug 2026, 19:36 UTC

Iovance Biotherapeutics reaches a new 52-week high above $7 amid positive results from the IOV-LUN-202 trial for metastatic NSCLC.

14 Aug 2026, 23:26 UTC

Iovance Biotherapeutics Inc. gains in after-market trading, reaching a 52-week high above $7 amid positive sentiment for IOV-LUN-202 and upcoming updates.